Pathophysiology of L-dopa-induced dyskinesias.
Bédard
P J
PJ
Centre de recherche du CHUQ, Pavillon CHUL, and Department of Medicine, Faculty of Medicine and Faculty of Pharmacy, Laval University, Quebec City, Canada.
Blanchet
P J
PJ
Lévesque
D
D
Soghomonian
J J
JJ
Grondin
R
R
Morissette
M
M
Goulet
M
M
Calon
F
F
Falardeau
P
P
Gomez-Mancilla
B
B
Doucet
J P
JP
Robertson
G S
GS
DiPaolo
T
T
D000818:Animals; D001667:Binding, Competitive; D003342:Corpus Striatum / Q000378:metabolism / Q000503:physiopathology*; D004298:Dopamine / Q000378:metabolism; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000493:pharmacokinetics; D004409:Dyskinesia, Drug-Induced / Q000209:etiology* / Q000503:physiopathology*; D005917:Globus Pallidus / Q000378:metabolism; D000882:Haplorhini; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000493:pharmacokinetics; D009434:Neural Pathways / Q000378:metabolism / Q000503:physiopathology*; D009474:Neurons / Q000378:metabolism; D020033:Protein Isoforms / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D018079:Receptors, GABA / Q000378:metabolism; D013378:Substantia Nigra / Q000378:metabolism / Q000503:physiopathology*
D018491:Dopamine Agonists; D020033:Protein Isoforms; D016760:Proto-Oncogene Proteins c-fos; D018079:Receptors, GABA; D007980:Levodopa; D004298:Dopamine